Biodesix, Inc. – Trademark Portfolio
Entity Type: 03
Biodesix, Inc. owns a portfolio of 57 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as IQLUNG, NODIFY, GENESTRAT, VERISTRAT, and DEEP MALDI. Of these, 15 are registered and 2 are pending. The portfolio spans 5 Nice Classification classes, led by Class 44 (Medical Services) and Class 10 (Medical Apparatus). Headquartered in Boulder, CO.
2970 Wilderness Place
Boulder, CO 80301
Showing of trademarks Trademarks
Trademark Classifications
Biodesix, Inc.'s trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Biodesix, Inc. have?
Biodesix, Inc. has 57 U.S. trademarks filed with the USPTO. Of these, 15 registered, 2 pending, 7 abandoned, 33 cancelled.
What trademark classes does Biodesix, Inc. file in?
Biodesix, Inc. files trademarks across 5 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 1 (Chemicals). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are Biodesix, Inc.'s most well-known trademarks?
Biodesix, Inc.'s registered trademark portfolio includes well-known marks such as IQLUNG, NODIFY, GENESTRAT, VERISTRAT, and DEEP MALDI. These are among 15 currently registered trademarks in the portfolio.
What is Biodesix, Inc.'s trademark registration success rate?
Biodesix, Inc. has a 27% trademark registration rate, with 15 out of 55 resolved applications resulting in successful registration. Currently, 2 applications are pending review.